Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 9, 2013, Pages 1111-1118

  Masuda, Kiyomi ^a   Aoki, Kazutaka ^a   Kamiko, Kazunari ^a   Takihata, Masahiro ^a   Ito, Yuzuru ^a   Nagakura, Mieko ^b   Kawasaki, Satsuki ^c   Akema, Noriko ^d   Hasegawa, Maki ^e   Nakajima, Shigeru ^f   Shinoda, Kazuaki ^f   Toumura, Shyoken ^g   Tsunoda, Seishi ^h   Enomoto, Hitoshi ⁱ   Shimotomai, Hidefumi ^j   Terauchi, Yasuo ^k  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Nagakura Clinic   (Japan)

^c Chigasaki Tokushukai Medical Center   (Japan)

^d IHI CORPORATION   (Japan)

^e Maki Clinic   (Japan)

^f Nakajima Clinic   (Japan)

^g Tsubakigaoka Clinic   (Japan)

^h Tsunoda Iin   (Japan)

ⁱ Enomoto Clinic   (Japan)

^j Shimotomai Clinic   (Japan)

^k YOKOHAMA CITY UNIVERSITY   (Japan)

more..

Author keywords

glucosidase inhibitor; Alogliptin; Diabetes; Drug adherence

Indexed keywords

ALBUMIN; ALOGLIPTIN; HEMOGLOBIN A1C; MIGLITOL; VOGLIBOSE;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DIABETIC PATIENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERVENTION STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ALPHA-GLUCOSIDASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; PROSPECTIVE STUDIES; SERUM ALBUMIN; TIME FACTORS; TREATMENT OUTCOME; URACIL;

EID: 84877913737     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.790365     Document Type: Article

References (24)

1. Macfarlane DP, Paterson KR, Fisher M. Oral anti diabetic agents as cardiovascular drugs. Diabetes Obes Metab 2007;9:23-30
2. Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166:1836-41
3. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005;27:1064-73
4. Nathan DM, Buse JB, Davidson MB. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006;29:1963-72
5. Aoki K, Kato H, Terauchi Y. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. Endocr J 2007;54:1009-14
6. Aoki K, Nakamura A, Ito S, et al. Administration of miglitol until 30 min after the start of a meal is effective in type 2 diabetic patients. Diabetes Res Clin Pract 2007;78:30-3
7. Aoki K, Nakajima S, Nezu U, et al. Comparison of pre-vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. Diabetes Obes Metab 2008;10:970-2
8. Aoki K, Muraoka T, Ito Y, et al. Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Intern Med 2010;49:1085-7
9. Masuda K, Aoki K, Terauchi Y. Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance (NGT), impaired fasting glucose (IFG) or impaired glucose tolerance (IGT). J Diabetes Invest 2011;2:435-40
10. Aoki K, Kamiyama H, Yoshimura K, et al. Miglitol administered before breakfast increased plasma active glucagon-like peptide-1 (GLP-1) levels after lunch in patients with Type 2 diabetes treated with sitagliptin. Acta Diabetol 2012;49:225-30
11. Aoki K, Terauchi Y. Effect of acarbose therapy once or twice a day on glycemic control in Japanese patients with type 2 diabetes. Jpn J Clin Pharmacol 2012;43:17-20
12. The Committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Invest 2010;1:212-28
13. Seino Y, Fujita T, Hiroi S, et al. Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study. Curr Med Res Opin 2011;27:1781-92
14. Seino Y, Fujita T, Hiroi S, et al. Alogliptin plus voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension. Curr Med Res Opin 2011;27:21-9
15. Narita T, Katsuura Y, Sato T, et al. Miglitol induces prolonged and enhanced glucagon-like peptide-1 and reduced gastric inhibitory polypeptide responses after ingestion of a mixed meal in Japanese Type 2 diabetic patients. Diabet Med 2009;26:187-8
16. Arakawa M, Ebato C, Mita T, et al. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects. Metabolism 2008;57:1299-306
17. Lee A, Patrick P, Wishart J, et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002;4:329-35
18. Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010;12:224-33
19. Astrup A, Rossner S, Van Gaal L, et al. NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-16
20. Rosenstock J, Klaff LJ, Schwartz S, et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care 2010;33:1173-5
21. Irwin N, Flatt PR. Evidence for beneficial effects of compromised gastric inhibitory polypeptide action in obesity-related diabetes and possible therapeutic implications. Diabetologia 2009;52:1724-31
22. Aoki K, Masuda K, Miyazaki T, et al. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 2010;57:667-72
23. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91:4612-19
24. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-42